Table 1 Summary of all recorded parameters, presented as percentage change from controls.

From: Aβ initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice

 

Parameter

Change from control, %

SEM

n

p value

Fig.

1

Extracellular glucose transient amplitude, slices, Aβ

57.7

4.13

21

<0.0001

1A

2

Extracellular lactate transient amplitude, slices, Aβ

67

9.85

7

<0.02

S1A,B

3

Extracellular glucose transient amplitude, in vivo, Aβ

248.5

45

5

<0.0005

1Biv

4

LFP train integral, in vivo, Aβ

101.4

7.644

5

0.8597

1Bv

5

NAD(P)H overshoot amplitude, Aβ

56.4

3.8

23

<0.0001

1C

6

NAD(P)H dip amplitude, Aβ

118.6

7.55

23

<0.03

1C

7

FAD undershoot amplitude, Aβ

73.1

4.32

7

<0.001

S1F

8

pO2 integral, Aβ

118.7

6

26

<0.005

1D

9

LFP train integral, slices, Aβ

102.6

3.96

21

0.11

1E

10

Extracellular glucose transient amplitude, slices, GSK2795039 + Aβ

109.5

10.2

7

0.39

2A

11

Extracellular glucose transient amplitude, in vivo, GSK2795039 + Aβ

91.44

5.94

5

0.22

2Biii

12

LFP train integral, in vivo, GSK2795039 + Aβ

126.8

27.3

5

0.625

2Biv

13

NAD(P)H overshoot amplitude, GSK2795039 + Aβ

125.2

16.47

8

0.17

2C

14

NAD(P)H dip amplitude, GSK2795039 + Aβ

103.6

5.841

8

0.5598

2C

15

pO2 integral, GSK2795039 + Aβ

100

3.677

4

0.995

2D

16

LFP train integral, slices, GSK2795039 + Aβ

82.09

4.711

8

<0.001

2E

17

Extracellular glucose transient amplitude, Aβ in Cybb(tm1din/J) mice

100.6

6.41

6

0.9309

2Fi

18

NAD(P)H overshoot amplitude, Aβ in Cybb(tm1din/J) mice

93.15

9.079

10

>0.9999

2Fii

19

NAD(P)H dip amplitude, Aβ in Cybb(tm1din/J) mice

107

4.527

10

0.1572

2Fii

20

pO2 integral, Aβ in Cybb(tm1din/J) mice

110.8

8.525

10

0.239

2Fiii

21

LFP train integral, Aβ in Cybb(tm1din/J) mice

114

7.044

18

0.0639

2Fiii

22

MDA, Aβ

273.2

101.4

7

<0.05

S2

23

MDA, GSK2795039 + Aβ

72.51

8.39

6

<0.03

S2

24

MDA, Aβ in Cybb(1tmDin/J) mouse slices

107

18.57

6

0.7201

S2

25

Accumulated Activity, 1 h post-injection, i.c.v. Aβ

325

60.79

14

<0.003

3C

26

Interictal spike rate, 1 h post-injection, i.c.v. Aβ

674.2

172.1

16

<0.002

3C

27

Accumulated Activity, 48 h post-injection, i.c.v. Aβ

184.3

21.55

14

<0.002

3D

28

Interictal spike rate, 48 h post-injection, i.c.v. Aβ

179.9

35.04

14

<0.05

3D

29

pHFO rate, 48 h post-injection, i.c.v. Aβ

304.4

66.26

13

<0.01

3D

30

Accumulated Activity, 1 h post-injection, i.c.v. GSK2795039 + Aβ

134.4

41.98

9

0.4357

3C

31

Interictal spike rate, 1 h post-injection, i.c.v. GSK2795039 + Aβ

269.2

73.05

10

0.0977

3C

32

Accumulated Activity, 48 h post-injection, i.c.v. GSK2795039 + Aβ

47.53

12.07

8

<0.004

3D

33

Interictal spike rate, 48 h post-injection, i.c.v. GSK2795039 + Aβ

11.16

3.412

8

<0.008

3D

34

pHFO rate, 48 h post-injection, i.c.v. GSK2795039 + Aβ

88.18

28.23

10

0.6853

3D

35

Accumulated Activity, 1 h post-injection, i.c.v. Vehicle

114.4

27.19

10

0.6092

3C

36

Interictal spike rate, 1 h post-injection, i.c.v. Vehicle

105.6

14.74

12

0.5557

3C

37

Accumulated Activity, 48 h post-injection, i.c.v. Vehicle

107

33.97

10

0.8422

3D

38

Interictal spike rate, 48 h post-injection, i.c.v. Vehicle

107.3

29.06

11

0.9502

3D

39

pHFO rate, 48 h post-injection, i.c.v. Vehicle

43.65

13.3

7

<0.006

3D

Back to article page